glp-1 agonist in esrd receptor agonists' impact on cardio-renal outcomes and mortality T2D with acute kidney disease CKJ REVIEW GLP-1 receptor agonists

Clinical trials have shown that Toujeo produces slightly fewer hypoglycemic events, particularly nocturnal hypoglycemia, compared to Lantus at equivalent doses

Clinical data shows that approximately 5% of tirzepatide users and a slightly higher percentage of semaglutide users experience noticeable hair loss

We can help you explore this uncharted territory and strategize for success

According to the warning, dulaglutide (the active ingredient in Trulicity) was found to cause an increased risk of thyroid C-cell tumors in male and female rates

The FDA Adverse Event Reporting System shows a likely link between GLP-1 RAs (specifically liraglutide) and increased risk of pancreatitis